Array Biopharma (NASDAQ: ARRY) reported Q3 EPS of ($0.21), $0.04 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $36.99 million.

For earnings history and earnings-related data on Array Biopharma (ARRY) click here.